2011
DOI: 10.1136/ard.2011.150326
|View full text |Cite
|
Sign up to set email alerts
|

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

Abstract: The results indicate that the type I IFN pathway is activated in patient subsets of five rheumatic diseases and suggest that these subsets may benefit from anti-IFN therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

18
274
1
7

Year Published

2012
2012
2016
2016

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 335 publications
(300 citation statements)
references
References 39 publications
18
274
1
7
Order By: Relevance
“…This cluster contains highly correlated genes such as IFRG28 (28 kDa interferon-responsive protein), IFI35 (interferoninduced protein 35), IFI44L (interferon-induced protein 44-like), IFIT1 (interferon-induced protein with tetratricopeptide repeats 1), IFIT2, IRF2 (interferon-regulatory factor 2), IRF7, GIP2 (interferon a-inducible protein 2), GIP3, SERPING1 (serine proteinase inhibitor clade G member 1, C1 inhibitor), OAS1 (29-59-oligoadenylate synthetase 1), OAS2, MX1 (Myxovirus resistance 1), ISG15 (interferon-induced protein 15) and RSAD2 (radical S-adenosyl methionine domain containing 2). These findings have now been replicated in several other studies using independent cohorts (Thurlings et al, 2010;O'Hanlon et al, 2011;Higgs et al, 2011;Vosslamber et al, 2011). Moreover, IFN-bioactivity was measured in RA serum.…”
Section: Gene Expression In Blood Cellssupporting
confidence: 70%
“…This cluster contains highly correlated genes such as IFRG28 (28 kDa interferon-responsive protein), IFI35 (interferoninduced protein 35), IFI44L (interferon-induced protein 44-like), IFIT1 (interferon-induced protein with tetratricopeptide repeats 1), IFIT2, IRF2 (interferon-regulatory factor 2), IRF7, GIP2 (interferon a-inducible protein 2), GIP3, SERPING1 (serine proteinase inhibitor clade G member 1, C1 inhibitor), OAS1 (29-59-oligoadenylate synthetase 1), OAS2, MX1 (Myxovirus resistance 1), ISG15 (interferon-induced protein 15) and RSAD2 (radical S-adenosyl methionine domain containing 2). These findings have now been replicated in several other studies using independent cohorts (Thurlings et al, 2010;O'Hanlon et al, 2011;Higgs et al, 2011;Vosslamber et al, 2011). Moreover, IFN-bioactivity was measured in RA serum.…”
Section: Gene Expression In Blood Cellssupporting
confidence: 70%
“…More recently, we have reported that treatment of patients with SLE with a neutralizing anti-IFN-a mAb reduces cutaneous inflammation and the expression of a number of key inflammatory genes in patients (29). Similarly, a peripheral IFN "gene signature" has also been described in patients with scleroderma (30), although the role of type I IFNs in the pathogenesis of this disease is at present unknown. To further understand the contribution of type I IFNs in scleroderma, we used a model of chronic immune GVHD (31) that mimics many aspects of SSc, including overexpression of type I IFN-inducible genes in skin.…”
Section: Discussionmentioning
confidence: 99%
“…IFN-␥ influences chromatin remodeling and enhance accumulation of follicular helper T-cells (T FH ) population during the formation of ectoid lymphoid follicles (23,24). The IFN-inducible gene signature is observed in rheumatoid arthritis (RA) and SLE and serves as a marker for disease severity in SLE (25)(26)(27).…”
Section: Ics In Cd4mentioning
confidence: 99%